Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05947708 · ClinicalTrials.gov registry record · NA

The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300

A NA study of End Stage Renal Disease on Dialysis, sponsored by Outset Medical.

Completed
Registry status
NA
Development phase
41
Enrollment target
1
Study location

NCT05947708 is a NA study of End Stage Renal Disease on Dialysis that has completed, run by Outset Medical. The registered enrollment target is 41 participants, below the 73-participant average among 9 other End Stage Renal Disease on Dialysis trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05947708, a NA study of End Stage Renal Disease on Dialysis, has completed, sponsored by Outset Medical.

COMPLETED
Registry status
NA
Development phase
41 participants
Enrollment target
1
Study location

Study Summary

Study Goal is to determine the impact of dialysate flow rate (Qd) on Subject reported dialysis related symptoms and on time to recovery post dialysis.

Interventions

  • DEVICE Dialysate Flow Rate

Study Locations (1)

California

  • Outset Medical - San Jose

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2019-09-15
Est. Completion 2020-01-15
Phase NA

Sponsor

Outset Medical

4 total trials

What the Registry Record Tells You About NCT05947708

The ClinicalTrials.gov registry entry for NCT05947708 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 73-participant average among 9 other End Stage Renal Disease on Dialysis trials with a reported enrollment target (44% lower). The listed sponsor is Outset Medical, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with End Stage Renal Disease on Dialysis appearing as the primary indexed condition, and to 1 intervention - of which Dialysate Flow Rate is the first listed.

NCT05947708 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05947708 about?

NCT05947708 is a clinical study titled "The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300". Study Goal is to determine the impact of dialysate flow rate (Qd) on Subject reported dialysis related symptoms and on time to recovery post dialysis.

What is the current status of trial NCT05947708?

This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2019-09-15. Estimated completion is 2020-01-15.

What conditions does trial NCT05947708 study?

This clinical trial studies the following conditions: End Stage Renal Disease on Dialysis.

What interventions are being tested in trial NCT05947708?

The interventions under investigation include: Dialysate Flow Rate (DEVICE).

Who is sponsoring clinical trial NCT05947708?

This trial is sponsored by Outset Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05947708 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End Stage Renal Disease on Dialysis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.